There will likely be more dilution for your plan, but no guarantee that more people means faster regulatory processing. I’d say not likely. Big pharma does have redundancy, paid for with revenues from a variety of revenue streams, and no doubt it helps, to some degree. But no doubt for a small company the comparable redundancy would increase the spending far beyond the benefit. Plus it’s a new conceptual product, personalized, with a complex trial. Redundancy does not speed regulatory review. Plus, at the end of the day, it is one or two or so people who look over everything and ensure it is all correct, whether at BP or a tiny company. There are always a key one or two people who have ultimate and key responsibility. You can’t do something this complex without core people who manage and review everything.
News 
Market Data 
Discover 
AI
